Question

(Show work and calculations) Amy Dyken, controller at Blue Pharmaceutical Industries, a public company, is currently...

(Show work and calculations)

Amy Dyken, controller at Blue Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blue’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017.

BLUE PHARMACEUTICAL INDUSTRIES
SELECTED BALANCE SHEET
INFORMATION
JUNE 30, 2017

Long-term debt
   Notes payable, 9%

$980,000

   8% convertible bonds payable

4,960,000

   9% bonds payable

5,940,000

     Total long-term debt

$11,880,000

Shareholders’ equity
   Preferred stock, 6% cumulative, $50 par value, 105,000 shares authorized, 26,250 shares issued and outstanding

$1,312,500

   Common stock, $1 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding

980,000

   Additional paid-in capital

4,020,000

   Retained earnings

5,930,000

     Total shareholders’ equity

$12,242,500


The following transactions have also occurred at Blue.

1. Options were granted on July 1, 2016, to purchase 220,000 shares at $16 per share. Although no options were exercised during fiscal year 2017, the average price per common share during fiscal year 2017 was $20 per share.
2. Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2016.
3. The preferred stock was issued in 2016.
4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2017.
5. The 980,000 shares of common stock were outstanding for the entire 2017 fiscal year.
6. Net income for fiscal year 2017 was $1,510,000, and the average income tax rate is 40%.


For the fiscal year ended June 30, 2017, calculate the following for Blue Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.)

(a) Basic earnings per share.

(b) Diluted earnings per share.

0 0
Add a comment Improve this question Transcribed image text
Answer #1
Net income after tax          1,510,000
Less: dividend to preferred stock (1312500*6%)                78,750
Net income available for common stock holders          1,431,250
Net income available for common stock holders          1,431,250
Divided by: weighted average share in common stock              980,000
Basic earnings per share $            1.4605
Stock options
Market value of option exercisable (220000*20)          4,400,000
Less: exercisable value of option (220000*16)          3,520,000
Value of option              880,000
Number of share adjusted (880000/20)                44,000
Convertible bond
Interest paid to bond (4960000*8%)              396,800
Less: tax on interest (396800*40%)              158,720
Adjustment in income for convertible bond              238,080
Conversion ratio                        50
Multiply by: Number of bond (4960000/1000)                  4,960
Number of share adjusted              248,000
Convertible preferred stock
There is No Convertible preferred stock
Instruments Increase in earning Increase in number of common shares Earning per incremental share (Increase in earning / increase in number of common shares)
Options                                          0                               44,000 0.00
Convertible bond                             238,080                             248,000 0.96
The order in which to include dilutive instruments (lowest Earning per incremental share considered First.)
1 Options
2 Convertible bond
Dilutive Earning per share
Adjusted Net income Potential common share Per share (Adjusted Net income / potential common share) Nature
As per Basic Earning per share                         1,431,250                             980,000 $                                              1.4605
Add: options                                          0                               44,000 Dilutive
                        1,431,250                         1,024,000 $                                              1.3977
Add: Convertible bond                             238,080                             248,000 Dilutive
                        1,669,330                         1,272,000 $                                              1.3124
Reported under financial statement
Basic earnings per share $                               1.46
Diluted Earnings per share $                               1.31
Add a comment
Know the answer?
Add Answer to:
(Show work and calculations) Amy Dyken, controller at Blue Pharmaceutical Industries, a public company, is currently...
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for? Ask your own homework help question. Our experts will answer your question WITHIN MINUTES for Free.
Similar Homework Help Questions
  • Amy Dyken, controller at Oriole Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Oriole Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Oriole’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Oriole Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 9% $980,000    8% convertible bonds payable 4,960,000    9% bonds payable 5,940,000      Total long-term debt $11,880,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...

  • Problem 16-5 Amy Dyken, controller at Flint Pharmaceutical Industries, a public company, is currently preparing the cal...

    Problem 16-5 Amy Dyken, controller at Flint Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Flint's financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. FLINT PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable $990,000 4,920,000 6,000,000 Total long-term debt $11,910,000 Shareholders' equity Preferred stock, 6% cumulative,...

  • Amy Dyken, controller at Pina Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Pina Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Pina’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. PINA PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% $1,020,000 9% convertible bonds payable 5,030,000 10% bonds payable 5,950,000 Total long-term debt $12,000,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...

  • Amy Dyken, controller at Metlock Pharmaceutical Industries, a public company, is currently preparing the calculation fo...

    Amy Dyken, controller at Metlock Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Metlock's financial statements. Below is selected financial information for the fiscal year ended June 30, 2017 METLOCK PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% 8% convertible bonds payable 10% bonds payable $1,020,000 5,080,000 6,110,000 $12,210,000 Total long-term debt Shareholders' equity Preferred stock, 6% cumulative, $50 par...

  • Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sandhill’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sandhill Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 10% $1,010,000    9% convertible bonds payable 5,030,000    10% bonds payable 5,990,000      Total long-term debt $12,030,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...

  • Amy Dyken controller at Sheridan Pharmaceutical Industries, a public company is currently preparing the calculation for...

    Amy Dyken controller at Sheridan Pharmaceutical Industries, a public company is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sheridan financial statements Below is selected financial information for the fiscal year ended June 30, 2020. Sheridan Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term diebt Notes payable, 10% 9X convertible bonds payable 10% bonds payable Total long-term debt $1.000.000 5,050,000 5.920,000 $11.970,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...

  • Problem 16-05 Amy Dyken, controller at Monty Pharmaceutical Industries, a public company, is currently preparing the...

    Problem 16-05 Amy Dyken, controller at Monty Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Monty's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Monty Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% 8% convertible bonds payable 11% bonds payable Total long-term debt $980,000 5,030,000 6,100,000 $12,110,000 Shareholders' equity Preferred stock, 6% cumulative,...

  • Amy Dyken, controller at Blossom Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Blossom Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blossom’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Blossom Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 10% $1,020,000    8% convertible bonds payable 5,080,000    10% bonds payable 6,110,000      Total long-term debt $12,210,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...

  • Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...

  • Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 11% $1,020,000    9% convertible bonds payable 5,020,000    11% bonds payable 6,120,000      Total long-term debt $12,160,000 Shareholders’ equity    Preferred stock, 5% cumulative, $50 par...

ADVERTISEMENT
Free Homework Help App
Download From Google Play
Scan Your Homework
to Get Instant Free Answers
Need Online Homework Help?
Ask a Question
Get Answers For Free
Most questions answered within 3 hours.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT